• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝细胞癌的分子标志物：作为诊断/预后标志物的新趋势！

Hepatocellular Carcinoma's Molecular Markers: The New Trend as Diagnostic/Prognostic Markers!

作者信息

Badwei Nourhan

机构信息

Tropical Medicine, Gastroenterology and Hepatology, Hepatoma Group, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

出版信息

J Clin Exp Hepatol. 2023 Jul-Aug;13(4):718-719. doi: 10.1016/j.jceh.2023.01.007. Epub 2023 Jan 17.

DOI:10.1016/j.jceh.2023.01.007
PMID:37440939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10333937/
Abstract

Hepatocellular carcinoma represents one of the serious and common liver diseases that need to be early diagnosed and promptly treated; Hence various researchers have paid great attention to the utility of molecular markers in the diagnosis and/or prognosis of hepatic neoplasms. Our letter focused on summarizing their role as diagnostic/prognostic tools in patients with hepatocellular tumours for a better outcome.Image 1.

摘要

肝细胞癌是需要早期诊断和及时治疗的严重且常见的肝脏疾病之一；因此，众多研究人员高度关注分子标志物在肝脏肿瘤诊断和/或预后方面的应用。我们的信函着重总结了它们作为肝细胞肿瘤患者诊断/预后工具的作用，以期获得更好的结果。图1。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21e1/10333937/ca0549d4ab39/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21e1/10333937/ca0549d4ab39/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21e1/10333937/ca0549d4ab39/ga1.jpg

相似文献

1
Hepatocellular Carcinoma's Molecular Markers: The New Trend as Diagnostic/Prognostic Markers!肝细胞癌的分子标志物：作为诊断/预后标志物的新趋势！
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):718-719. doi: 10.1016/j.jceh.2023.01.007. Epub 2023 Jan 17.
2
Hepatoid adenocarcinoma: A wolf in hepatocellular carcinoma's clothing.肝样腺癌：披着肝细胞癌外衣的“狼”。
JGH Open. 2022 Sep 8;6(10):727-729. doi: 10.1002/jgh3.12813. eCollection 2022 Oct.
3
Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma's prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response.缺氧驱动的长链非编码 RNA CTD-2510F5.4：在肝细胞癌的预后分层、细胞行为、肿瘤微环境和治疗反应中具有潜在作用的一个因素。
Mol Biol Rep. 2024 Aug 12;51(1):905. doi: 10.1007/s11033-024-09826-6.
4
The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection.KLF4 作为抑癌基因与根治性切除术后肝细胞癌预后的关系。
Aging (Albany NY). 2020 Aug 5;12(15):15566-15580. doi: 10.18632/aging.103592.
5
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.肝细胞癌的管理：免疫组化标志物对术后生存的预测价值
World J Hepatol. 2015 Jan 27;7(1):7-27. doi: 10.4254/wjh.v7.i1.7.
6
Autophagy facilitates the sorafenib resistance of hepatocellular carcinoma cells.自噬促进肝癌细胞对索拉非尼的耐药性。
West Indian Med J. 2013 Nov;62(8):698-700. doi: 10.7727/wimj.2013.040.
7
Elevated CTSL2 expression is associated with an adverse prognosis in hepatocellular carcinoma.CTSL2表达升高与肝细胞癌的不良预后相关。
Int J Clin Exp Pathol. 2018 Aug 1;11(8):4035-4043. eCollection 2018.
8
Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.不同表型循环肿瘤细胞在肝细胞癌中的诊断价值。
J Gastrointest Surg. 2019 Dec;23(12):2354-2361. doi: 10.1007/s11605-018-04067-y. Epub 2019 Feb 25.
9
Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.癌症干细胞生物标志物的表达作为一种用于肝细胞癌正确治疗方法的工具。
Oncoscience. 2015 May 15;2(5):443-456. doi: 10.18632/oncoscience.163. eCollection 2015.
10
Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.移民对美国肝细胞癌的临床表现及治疗结果的影响。
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):24-28. doi: 10.1097/MEG.0000000000001212.

本文引用的文献

1
Current and Emerging Molecular Markers of Liver Diseases: A Pathogenic Perspective.肝脏疾病的当前及新出现的分子标志物：致病机制视角
Gene Expr. 2022;21(1):9-19. doi: 10.14218/gejlr.2022.00010. Epub 2022 Sep 28.
2
Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review.实体瘤中免疫检查点抑制剂的再治疗：一项系统综述。
Ther Adv Med Oncol. 2020 Nov 27;12:1758835920975353. doi: 10.1177/1758835920975353. eCollection 2020.
3
Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.
甲胎蛋白、甲胎蛋白异质体 3%和 DCP 联合应用诊断肝细胞癌的评价：一项荟萃分析。
Biomed Res Int. 2020 Sep 17;2020:5087643. doi: 10.1155/2020/5087643. eCollection 2020.
4
Clinical significance of miR-1180-3p in hepatocellular carcinoma: a study based on bioinformatics analysis and RT-qPCR validation.miR-1180-3p 在肝细胞癌中的临床意义：基于生物信息学分析和 RT-qPCR 验证的研究。
Sci Rep. 2020 Jul 14;10(1):11573. doi: 10.1038/s41598-020-68450-z.
5
The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.非酒精性脂肪性肝病无肝硬化患者肝细胞癌的特征和危险因素。
J Gastroenterol Hepatol. 2020 May;35(5):862-869. doi: 10.1111/jgh.14867. Epub 2019 Dec 3.
6
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
7
Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas.胃肠道、肝脏、胆道和胰腺肿瘤病理学中的实用免疫组织化学
Arch Pathol Lab Med. 2017 Sep;141(9):1155-1180. doi: 10.5858/arpa.2016-0489-RA.
8
Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization.具有干性标志物的肝细胞癌在缺氧状态下预后较差：对经动脉化疗栓塞的抵抗性。
Mod Pathol. 2016 Sep;29(9):1038-49. doi: 10.1038/modpathol.2016.111. Epub 2016 Jun 17.
9
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.肝癌：与肥胖、脂肪肝和肝硬化的关联。
Annu Rev Med. 2016;67:103-17. doi: 10.1146/annurev-med-090514-013832. Epub 2015 Oct 14.
10
Chromosomal instability, telomere shortening, and inactivation of p21(WAF1/CIP1) in dysplastic nodules of hepatitis B virus-associated multistep hepatocarcinogenesis.乙型肝炎病毒相关多步骤肝癌发生发育异常结节中的染色体不稳定性、端粒缩短及p21（WAF1/CIP1）失活
Mod Pathol. 2009 Aug;22(8):1121-31. doi: 10.1038/modpathol.2009.76. Epub 2009 May 22.